Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Haw ParHAWPF 83 Equity-to-Asset is 0.97 as of Jun. 2026, which is at its 10-year median of 0.97. GuruFocus rates HAWPF with a GF Score™ of 83/100 and a GF Value™ of $9.22 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Haw Par ranks better than 99.2% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Haw Par's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $3,683.3 Mil. Haw Par's Total Assets for the quarter that ended in Jun. 2026 was $3,787.3 Mil.
Therefore, Haw Par's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.97.
The historical rank and industry rank for Haw Par's Equity-to-Asset or its related term are showing as below:
HAWPF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.94 Med: 0.97 Max: 0.98
Current: 0.97
During the past 13 years, the highest Equity to Asset Ratio of Haw Par was 0.98. The lowest was 0.94. And the median was 0.97.
HAWPF's Equity-to-Asset is ranked better than 99.2% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs HAWPF: 0.97
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Haw Par Equity-to-Asset Related Terms
Haw Par Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Haw Par's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAWPF vs LLY, JNJ, ABBV: Equity-to-Asset Comparison
For the Drug Manufacturers - General subindustry, Haw Par's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haw Par Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haw Par's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Haw Par's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Haw Par's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haw Par (HAWPF) has a Equity-to-Asset of 0.97 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Haw Par and its competitors. This is near median its historical median of 0.97. Over the past decade, Haw Par's Equity-to-Asset has ranged from 0.94 to 0.98. According to the industry distribution chart, Haw Par ranks #8 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 0.8%.
Is Haw Par's Equity-to-Asset too high?
Haw Par's current Equity-to-Asset of 0.97 is near median its 10-year median of 0.97. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 0.98. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Haw Par's value of 0.97 is 61.7% above this industry median. Based on the distribution chart, Haw Par ranks #8 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Haw Par has a GF Score™ of 83/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haw Par's Equity-to-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Haw Par ranks #8 out of 1006 companies for Equity-to-Asset. This places Haw Par in the top 1% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.60. Haw Par's value of 0.97 is 61.7% above this benchmark. Historically, Haw Par's own Equity-to-Asset has ranged from 0.94 to 0.98 over the past decade. While the company's 10-year median is 0.97 vs. the industry median of 0.60, Haw Par has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haw Par's current Equity-to-Asset of 0.97 is 61.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Haw Par and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haw Par's current Equity-to-Asset is 0.97, which is near median its own 10-year median of 0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Based on GuruFocus' analysis, Haw Par (HAWPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.22, compared to a current price of $12.58 — trading 36.4% above its estimated fair value. The current Equity-to-Asset is 0.97, which is near median its 10-year median of 0.97 and 61.7% above the Drug Manufacturers industry median of 0.60. Haw Par's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Haw Par (HAWPF), the current Equity-to-Asset is 0.97 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haw Par (HAWPF) Overvalued in 2026?
Based on GuruFocus' analysis, Haw Par stock appears to be overvalued.
The current stock price of $12.58 is trading 36.4% above its estimated GF Value™ of $9.22.
GuruFocus considers Haw Par to be Significantly Overvalued.
Key valuation signals for HAWPF:
Equity-to-Asset: 0.97 (near median its 10-year median of 0.97)
GF Value™: $9.22 vs. price of $12.58 (36.4% above fair value)
Industry Position: 61.7% above the Drug Manufacturers median (#8 of 1006)
No single metric tells the full story. See the HAWPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
83GF Score
Get the complete analysis for HAWPF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAWPF has been successfully added to your 
